<DOC>
	<DOCNO>NCT00550459</DOCNO>
	<brief_summary>Demonstrate improvement composite score validate neurocognitive test elderly subject chronic sub-clinical ( i.e. , asymptomatic ) hyponatremia .</brief_summary>
	<brief_title>Effects Titrated Oral Tolvaptan 15-60 mg Once Daily ( QD ) Cognitive Neurological Function Elderly Hyponatremic Patients</brief_title>
	<detailed_description>Subjects randomize , stratification baseline sodium &lt; 130 ≥ 130 mEq/L [ mmol/L ] receive either tolvaptan 15 mg tablet match placebo tablet dose 15 , 30 60 mg 21 day . During period , fluid restriction loosen suspend , subject 's response therapy evaluate , typically first day therapy . Fluid restriction may reinstituted time subject whose sodium fail improve worsens study therapy . A forced-titration 60 mg study drug day 3 7 base subject 's serum sodium Subjects enter study serum sodium concentration le 130 mEq/L [ mmol/L ] may fluid restricted necessary discretion Investigator . Subjects monitor closely first 24 hour treatment dose titration . The total dosing duration 21 day ( plus 3 day treatment window ) . Subjects return clinic Day 22 ( +3 day ) assessment complete follow-up visit Day 28 ( +2 day ) .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Women men 50 year age old . Serum Sodium ≥123 ≤ 134 mEq/L [ mmol/L ] screen baseline . Subjects serum sodium concentration ≥118 ≤122 mEq/L [ mmol/L ] screen baseline may enter trial base consultation approval study medical monitor . Conditions history may present safety concern subject offspring extreme susceptibility hypotension sudden fluid loss ( aquaresis ) . Hyponatremia acute , easily reversible , artifactual , due condition associate vasopressin excess likely respond aquaretic therapy . Conditions associate independent imminent risk morbidity mortality . Conditions may confound assessment endpoint , history poor compliance , participation clinical trial believe PI Sponsor likely confound endpoint assessment . Conditions may confound primary endpoint cognitive function .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hyponatremia</keyword>
	<keyword>Cognitive</keyword>
	<keyword>Neurological Function</keyword>
	<keyword>Elderly</keyword>
</DOC>